wait, wait, wait before we espouse a valuation:
Post# of 148147
Let's create a valuation of each indication, add them up and then apply a firesale discount.
Already been mentioned breast cancer has a value of $30/share for CYDY
1. agree / disagree
2. is there an indication valuable that we can agree is higher than breast cancer?
Since we will never agree on any of these, we can at least get a feel for low ball / high ball estimates of each indication.
As a leap of faith, pulling it out of mine arse $100/share is not crazy, if, i say if, breast cancer is $30/share.
A low ball of $10 would be crazy if, i say if, breast cancer is $30/share
Every time Scott speaks he defines Leronlimab as multiple indications. It would be irresponsible to sell the whole kitty for one indication.